The Crohn’s and Colitis Foundation of Canada and Vertex Pharmaceuticals (MA) Announce Collaboration to Fund Research in Inflammatory Bowel Disease

TORONTO & LAVAL, Quebec--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated and the Crohn’s and Colitis Foundation of Canada (CCFC) today announced a new collaboration to fund novel research aimed at identifying the underlying disease mechanisms and drivers of inflammatory bowel disease (IBD), specifically Crohn’s disease and ulcerative colitis.

Back to news